Domperidone in Refractory Gastroparesis

Inclusion Criteria: * Male or female * Age 18 and older * Symptoms or manifestations secondary to motility disorders of the upper GI tract. These include gastroparesis, functional dyspepsia, gastroesophageal reflux disease that are refractory to standard therapy. * Patients must have a comprehensive evaluation to eliminate other causes of their symptoms. This includes a history and physical examination. A recent (within 3 years) evaluation of the upper GI tract with either upper endoscopy or upper GI radiographic series. Baseline blood tests suggested are electrolytes, magnesium, and prolactin level. * Patient has signed informed consent for the administration of domperidone that informs the patient of potential adverse events including: * Increased prolactin levels * Breast changes * Extrapyramidal side effects * Cardiac arrhythmias including QT prolongation (increased risk with the drugs listed in the appendix) Exclusion Criteria: * History of, or current, arrhythmias including ventricular tachycardia, ventricular fibrillation and Torsade des Pointes. Patients with minor forms of ectopy (PACs) are not necessarily excluded. * Clinically significant bradycardia, sinus node dysfunction, or heart block. Prolonged QTc (QTc\>450 milliseconds for males, QTc\>470 milliseconds for females) * Clinically significant electrolyte disorders. These include significant hypokalemia, hyperkalemia, hypomagnesemia, and hypermagnesemia that cannot be corrected with treatment of these electrolyte abnormalities. * Gastrointestinal hemorrhage or obstruction. * Presence of a prolactinoma (prolactin-releasing pituitary tumor). * Pregnant or breast feedings female. * Known allergy to domperidone